We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is tran... Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Show more
Ask ADVFN Intelligence (AI)
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today...
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety...
Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB...
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior...
- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.04 | -1.70212765957 | 2.35 | 2.43 | 2.17 | 284935 | 2.31502529 | CS |
| 4 | -0.4701 | -16.9094636884 | 2.7801 | 9.29 | 1.8 | 1083915 | 2.10791536 | CS |
| 12 | -11.29 | -83.0147058824 | 13.6 | 14.9999 | 1.8 | 435628 | 4.02156619 | CS |
| 26 | -14.43 | -86.2007168459 | 16.74 | 20.63 | 1.8 | 241395 | 6.12429235 | CS |
| 52 | -6.91 | -74.9457700651 | 9.22 | 26.3789 | 1.8 | 141184 | 7.79326598 | CS |
| 156 | -11.19 | -82.8888888889 | 13.5 | 26.3789 | 1.8 | 112929 | 7.71080032 | CS |
| 260 | -11.19 | -82.8888888889 | 13.5 | 26.3789 | 1.8 | 112929 | 7.71080032 | CS |
tw0122
17 hours ago
Covid19freak
1 month ago
JcOg323
1 month ago
Monksdream
4 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
